Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Heat Biologics, Inc. (HTBX)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
2.3800+0.0100 (+0.42%)
At close: 04:00PM EDT
Advertisement
Full screen
Loading interactive chart...
  • Zacks Small Cap Research

    NHWK: Name Change and New Facility

    By John Vandermosten, CFA NYSE:NHWK READ THE FULL NHWK RESEARCH REPORT The recently renamed NightHawk Biosciences, Inc. (NYSE:NHWK) reported first quarter 2022 results on May 16, 2022 and filed its Form 10-Q with the SEC. It has been a whirlwind year for the company as it made an acquisition, expanded its manufacturing efforts, converted into a vertically integrated biosciences company and

  • GlobeNewswire

    NightHawk Biosciences Provides First Quarter 2022 Business Update

    DURHAM, N.C., May 16, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today provided strategic, financial, and operational updates for the first quarter ended March 31, 2022. Jeff Wolf, Chief Executive Officer of NightHawk, commented, “We are extremely proud of the progress we have made this quarter to transition NightHawk into a fully-integrated biopha

  • GlobeNewswire

    NightHawk Biosciences to Present at the 4th Annual Treg Directed Therapies Summit on PTX-35

    DURHAM, N.C., May 10, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Matthew Seavey, Ph.D., MBA, NightHawk’s Vice President of Research will be presenting data on PTX-35, and serving on an expert panel discussing modes of Treg activation, at the 4th Annual Treg Directed Therapies Summit being held on May 17-19th in Boston. PTX-35 i

Advertisement
Advertisement